160 related articles for article (PubMed ID: 38149471)
1. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
Ho IW; Pan YL; Lai JI; Liu CY
Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
Ma WL; Lin CC; Hsu FM; Lee JM; Chen JS; Huang YL; Chang YL; Chang CH; Yang JC
Cancer Med; 2022 Sep; 11(18):3445-3456. PubMed ID: 35348307
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
Wang Y; Zhang X; Tian D; Han S; Zhang J; Nie J; Dai L; Hu W; Chen X; Ma X; Tian G; Wu D; Zhang Z; Long J; Fang J
Cancer Med; 2023 Feb; 12(3):2303-2311. PubMed ID: 35924403
[TBL] [Abstract][Full Text] [Related]
4. Optimal first-line treatment for advanced thymic carcinoma.
Yang X; Zhuo M; Shi A; Yang S; Wang Z; Wu M; An T; Wang Y; Li J; Zhong J; Chen H; Jia B; Dong Z; Zhao J
Thorac Cancer; 2019 Nov; 10(11):2081-2087. PubMed ID: 31574576
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatments for thymoma and thymic carcinoma: A systematic review.
Berghmans T; Durieux V; Holbrechts S; Jungels C; Lafitte JJ; Meert AP; Moretti L; Ocak S; Roelandts M; Girard N
Lung Cancer; 2018 Dec; 126():25-31. PubMed ID: 30527189
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.
Hao Y; Si J; Jin J; Wei J; Xiang J; Xu C; Song Z
Curr Oncol; 2022 Dec; 29(12):9452-9460. PubMed ID: 36547157
[TBL] [Abstract][Full Text] [Related]
7. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Wang Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Han S; Long J; Zhang Z; Fang J
Thorac Cancer; 2019 Jan; 10(1):17-23. PubMed ID: 30411854
[TBL] [Abstract][Full Text] [Related]
10. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy.
Okuma Y; Saito M; Hosomi Y; Sakuyama T; Okamura T
J Cancer Res Clin Oncol; 2015 Feb; 141(2):323-31. PubMed ID: 25146529
[TBL] [Abstract][Full Text] [Related]
11. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Hirai F; Seto T; Inamasu E; Toyokawa G; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Oct; 34(10):5743-7. PubMed ID: 25275083
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
Tateishi K; Ko R; Shukuya T; Okuma Y; Watanabe S; Kuyama S; Murase K; Tsukita Y; Ashinuma H; Nakagawa T; Uematsu K; Nakao M; Mori Y; Kaira K; Mouri A; Miyabayashi T; Sakashita H; Matsumoto Y; Tanigawa T; Koizumi T; Morita S; Kobayashi K; Nukiwa T; Takahashi K;
Oncologist; 2020 Apr; 25(4):e668-e674. PubMed ID: 31771990
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature.
Watanabe K; Shinkai M; Goto H; Yoshikawa S; Yamaguchi N; Hara Y; Shinoda M; Moriyama Y; Rubin BK; Ishigatsubo Y; Kaneko T
Tumori; 2013; 99(4):e172-6. PubMed ID: 24326856
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
Okuma Y; Hosomi Y; Takagi Y; Iguchi M; Okamura T; Shibuya M
Lung Cancer; 2011 Dec; 74(3):492-6. PubMed ID: 21665316
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and prognosis in advanced thymic carcinoma patients.
Song Z; Yu X; Zhang Y
Clinics (Sao Paulo); 2015 Dec; 70(12):775-80. PubMed ID: 26735216
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
Ko R; Shukuya T; Okuma Y; Tateishi K; Imai H; Iwasawa S; Miyauchi E; Fujiwara A; Sugiyama T; Azuma K; Muraki K; Yamasaki M; Tanaka H; Takashima Y; Soda S; Ishimoto O; Koyama N; Morita S; Kobayashi K; Nukiwa T; Takahashi K;
Oncologist; 2018 Oct; 23(10):1210-1217. PubMed ID: 29567820
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
Jung HA; Kim M; Kim HS; Kim JH; Choi YH; Cho J; Park JH; Park KU; Ku BM; Park S; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2023 Feb; 18(2):223-231. PubMed ID: 36307042
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.
Kanda S; Koizumi T; Komatsu Y; Yoshikawa S; Okada M; Hatayama O; Yasuo M; Tsushima K; Urushihata K; Kubo K; Sasabayashi M; Takamizawa A
Anticancer Res; 2007; 27(4C):3005-8. PubMed ID: 17695487
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
